APA (7th ed.) Citation

Sepideh Paybast, Nasim Rezaeimanesh, & Abdorreza Naser Moghadasi. (2025). De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: The initial Iranian experience. Babol University of Medical Sciences.

Chicago Style (17th ed.) Citation

Sepideh Paybast, Nasim Rezaeimanesh, and Abdorreza Naser Moghadasi. De-escalation of Anti-CD20 Monoclonal Antibodies to Low-moderate Efficacy Disease-modifying Treatments (DMTs) in Patients with Relapse-remitting Multiple Sclerosis: The Initial Iranian Experience. Babol University of Medical Sciences, 2025.

MLA (9th ed.) Citation

Sepideh Paybast, et al. De-escalation of Anti-CD20 Monoclonal Antibodies to Low-moderate Efficacy Disease-modifying Treatments (DMTs) in Patients with Relapse-remitting Multiple Sclerosis: The Initial Iranian Experience. Babol University of Medical Sciences, 2025.